GeneHealth - Your precision medicine

Osteogenesis Imperfecta Type 13

Disease Details

Family Health Simplified

Buy Membership

Description: Osteogenesis imperfecta type 13 is a rare genetic disorder characterized by extreme bone fragility due to defects in collagen formation.
Type: Osteogenesis imperfecta type 13 is transmitted in an autosomal recessive manner.
Signs And Symptoms: Osteogenesis imperfecta type 13 is a genetic disorder characterized primarily by brittle bones that are prone to fractures. The signs and symptoms of this condition may include:

- Frequent fractures, often from minimal or no trauma
- Bone deformities
- Short stature
- Blue sclerae (a blue tint to the whites of the eyes)
- Hearing loss
- Loose joints and muscle weakness
- Possible dentinogenesis imperfecta (brittle teeth)

The severity of symptoms can vary widely among affected individuals, ranging from mild to severe.
Prognosis: Osteogenesis imperfecta type 13 (OI type 13) is a rare genetic disorder characterized by brittle bones that are prone to fractures, often with minimal or no trauma. It is caused by mutations in the SP7 gene, which plays a crucial role in bone formation.

**Prognosis:**
The prognosis for individuals with OI type 13 can vary widely. Factors influencing the prognosis include the severity of bone fragility, the frequency and management of fractures, and associated complications. Severe cases may face limitations in mobility and growth, while milder cases may achieve a more typical range of function. Comprehensive medical management, including orthopedic care, physical therapy, and sometimes surgical intervention, can improve outcomes and quality of life.

**Note:**
There seems to be a misunderstanding with the term "nan." If you intended to ask for specific information or another aspect of OI type 13, please clarify, and I'd be happy to provide more details.
Onset: Osteogenesis imperfecta type 13 typically has an onset in infancy or early childhood.
Prevalence: Osteogenesis imperfecta type 13 is an extremely rare subtype of osteogenesis imperfecta, a genetic disorder characterized by fragile bones. Its exact prevalence is not well-documented due to the rarity of the condition.
Epidemiology: Osteogenesis imperfecta type 13 (OI type 13) is an ultrarare form of osteogenesis imperfecta, a genetic disorder characterized by fragile bones that break easily. Due to its extreme rarity, specific epidemiological data, such as prevalence or incidence rates for OI type 13, is not well-documented. Cases are typically identified through genetic testing and research studies, with only a limited number of individuals diagnosed worldwide.
Intractability: Osteogenesis imperfecta type 13 is considered a severe form of osteogenesis imperfecta, characterized by extremely fragile bones and various other symptoms. While there are treatments available to manage symptoms and improve quality of life, such as bisphosphonates, physical therapy, and surgical interventions, the disease itself cannot currently be cured. Therefore, it can be considered intractable in terms of being unable to be completely eradicated or resolved.
Disease Severity: Osteogenesis imperfecta type 13 (OI type 13) is a severe form of osteogenesis imperfecta characterized by extremely fragile bones, frequent fractures, and bone deformities. This type is typically associated with prenatal or perinatal onset and can be life-threatening due to complications related to fractures and respiratory issues.
Healthcare Professionals: Disease Ontology ID - DOID:0110342
Pathophysiology: Osteogenesis imperfecta type 13 is primarily caused by mutations in the SP7 gene, which encodes a transcription factor essential for bone formation and osteoblast differentiation. The defective SP7 gene disrupts the normal production and function of osteoblasts, leading to the impaired synthesis of collagen type I. Collagen type I is crucial for bone strength and structure, and its deficiency results in the characteristic brittle bones and frequent fractures observed in individuals with this condition.
Carrier Status: Osteogenesis imperfecta type 13 is an autosomal recessive disorder. This means that carriers of a single mutated allele typically do not show symptoms but can pass the mutated gene to their offspring. A person must inherit two copies of the mutated gene, one from each parent, to be affected by the disorder. Hence, carriers have one normal allele and one mutated allele.
Mechanism: Osteogenesis imperfecta type 13 (OI type 13) is a rare genetic disorder primarily characterized by increased bone fragility, leading to frequent fractures. It is caused by mutations in the SP7 gene, which encodes the transcription factor Osterix. Osterix plays a critical role in bone formation by regulating the differentiation of precursor cells into osteoblasts, the cells responsible for bone synthesis.

Molecular mechanisms:
- Mutations in the SP7 gene disrupt the normal function of Osterix, leading to impaired osteoblast differentiation and activity.
- The reduced function of osteoblasts affects the deposition of bone matrix, resulting in bones that are less dense and more prone to fractures.
- The altered regulation of bone-specific genes due to defective Osterix impacts the overall bone development and maintenance.

This impaired process of bone formation and remodeling contributes to the skeletal abnormalities and fragility observed in individuals with OI type 13.
Treatment: Osteogenesis imperfecta type 13 is a rare genetic disorder characterized by fragile bones that break easily. There is no cure, but treatment focuses on managing symptoms and preventing complications. Approaches may include:

1. **Medications:** Bisphosphonates to increase bone density and reduce fracture risk.
2. **Physical Therapy:** To strengthen muscles and improve mobility.
3. **Orthopedic Interventions:** Surgical procedures like rodding to stabilize and correct bone deformities.
4. **Assistive Devices:** Braces, wheelchairs, or other aids to support mobility and function.
5. **Lifestyle and Supportive Care:** Adequate nutrition, particularly calcium and vitamin D, and safe, low-impact exercises.

Consultation with a multidisciplinary team of healthcare providers is essential for optimal management.
Compassionate Use Treatment: Osteogenesis imperfecta type 13 (OI type 13) is a rare form of osteogenesis imperfecta characterized by fragile bones that break easily. Compassionate use treatment and off-label or experimental treatments for OI type 13 may include:

1. **Bisphosphonates**: Frequently used off-label to increase bone density and reduce fracture risk, although primarily approved for osteoporosis.
2. **Teriparatide**: An anabolic agent that stimulates bone formation, sometimes considered off-label for OI.
3. **Denosumab**: A monoclonal antibody that may be used experimentally to reduce bone resorption.
4. **Bone Marrow Transplant**: Investigated experimentally for its potential to improve bone strength by introducing healthy osteoblasts.
5. **Gene Therapy**: Still in experimental stages, aimed at correcting the genetic defects causing OI type 13.
6. **Cell Therapy**: Utilizing mesenchymal stem cells to promote bone regeneration, also an experimental treatment.

Compassionate use programs allow access to these treatments under specific, often critical conditions when no other options are available. Always consult with healthcare professionals for personalized treatment plans.
Lifestyle Recommendations: For individuals with osteogenesis imperfecta type 13, lifestyle recommendations typically involve measures to manage symptoms, maintain quality of life, and prevent complications. These recommendations may include:

1. **Regular Monitoring**: Frequent check-ups with healthcare providers to monitor bone health and development.

2. **Physical Therapy**: Engaging in tailored physical therapy to improve muscle strength, joint function, and mobility while minimizing the risk of fractures.

3. **Safe Exercises**: Participating in low-impact exercises such as swimming or cycling, which can help maintain fitness without putting undue stress on the bones.

4. **Balanced Diet**: Maintaining a diet rich in calcium and vitamin D to support bone health. Nutritional supplements may be recommended if dietary intake is insufficient.

5. **Medication**: Using medications like bisphosphonates under medical supervision to strengthen bones and reduce fracture risk.

6. **Adaptive Equipment**: Utilizing orthopedic braces, mobility aids, and other adaptive devices to navigate daily activities safely.

7. **Home Environment**: Making modifications to the home environment to reduce fall risks, such as securing carpets, installing grab bars, and ensuring adequate lighting.

8. **Preventive Care**: Avoiding activities with a high risk of trauma or falls and using protective gear when necessary.

9. **Support Networks**: Seeking support from patient advocacy groups, counseling, and connecting with others who have osteogenesis imperfecta for emotional and practical support.

10. **Education and Awareness**: Educating family members, schools, and employers about the condition to ensure appropriate accommodations and understanding of potential needs.

Following these lifestyle recommendations can help manage osteogenesis imperfecta type 13 more effectively and enhance overall well-being. Always consult with healthcare professionals to tailor guidelines to individual needs.
Medication: Osteogenesis imperfecta type 13 is a rare genetic disorder characterized by fragile bones that break easily. Treatment often focuses on managing symptoms and improving quality of life rather than curing the disease. Medications that may be used include:

1. **Bisphosphonates**: These drugs, such as pamidronate or alendronate, help to increase bone density and reduce fracture rates.
2. **Calcium and Vitamin D Supplements**: These are often recommended to support bone health.

It's important to consult with a healthcare provider for personalized treatment plans as the management of osteogenesis imperfecta type 13 is complex and must be tailored to individual needs.
Repurposable Drugs: Osteogenesis imperfecta type 13 (OI type 13) is a rare genetic disorder characterized by bone fragility and deformities. It is caused by mutations in the SP7 gene, which encodes the transcription factor osterix necessary for bone formation. There are limited specific treatments for OI type 13, but some repurposable drugs and experimental treatments under investigation include:

1. **Bisphosphonates:** These drugs, such as pamidronate and zoledronic acid, are typically used in other forms of OI to increase bone density and reduce fracture rates.
2. **Teriparatide:** A recombinant form of parathyroid hormone, which has been investigated for its potential to stimulate bone formation.
3. **Denosumab:** This antibody inhibits RANKL and has been used off-label to treat cases of severe osteoporosis and may have potential for OI.

It is important to note that while these medications can help manage some symptoms, they do not address the underlying genetic cause of the disease. Clinical trials and further research are essential for developing more targeted treatments. Always consult healthcare professionals for the most appropriate treatment options.
Metabolites: Osteogenesis imperfecta type 13 (OI type 13) is a rare genetic disorder characterized by brittle bones and other connective tissue abnormalities. There isn't specific information about unique metabolites directly associated with OI type 13. It is generally caused by mutations in the PLS3 gene and less commonly associated with biochemical anomalies in metabolic pathways. For precise details on metabolic changes, further research or consultation with clinical studies would be recommended.
Nutraceuticals: There is no specific nutraceutical treatment for osteogenesis imperfecta type 13. Management generally includes medications like bisphosphonates, physical therapy, and sometimes surgical interventions to manage fractures and improve bone density. Nutraceuticals are not a standard part of the treatment regimen for this genetic condition. However, maintaining a balanced diet with adequate calcium and vitamin D can support overall bone health. Always consult with a healthcare provider for personalized medical advice.
Peptides: Osteogenesis imperfecta type 13 is a subtype of osteogenesis imperfecta (OI) caused by mutations in the SPARC gene. This autosomal recessive disorder affects collagen formation, leading to brittle bones and frequent fractures. Peptides and nanotechnology are not standard treatments for this condition, with current management primarily focusing on fracture prevention, physical therapy, and sometimes surgical interventions. Research into advanced therapies, including the use of peptides and nanotechnology, is ongoing but not yet established for OI type 13.